3,500 Years of Artificial Tears
After three millennia of battling the discomfort and irritation of dry eye, is ophthalmology any closer to a solution?
Nicox's shareholders approve acquisition of Aciex Therapeutics, Inc.
The acquisition of Aciex represents a significant step forward in Nicox’s strategy of creating an international ophthalmic company
RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy
Continuing to show positive results in Phase 3 will be an important breakthrough for treating NK
Guidelines for Writing Protocols
The protocol is the operating manual for a clinical trial, and every detail must be considered.
Leveraging Ex-U.S. Deals
Through this brief column, we hope that you’ll continue to glean a few insights that may help your ophthalmic program best navigate early stage business planning and development
Thoughts on Healing the Wounded Cornea
A look at the mechanism behind neurotrophic keratitis as well as current and future methods for treating it.
A Close Look at Pseudoexfoliation
This disease is linked to vision loss, hearing loss and cataract. Learning more about it may help lead to better treatments.
The Basics of a Pre-IND Meeting
Meetings with regulatory boards provide guidance to researchers who seek to comply with regulatory requirements and ease the drug approval process.